Group A + Group B
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchiectasis Adult
Conditions
Bronchiectasis Adult
Trial Timeline
Jun 1, 1996 → Sep 7, 1999
NCT ID
NCT03383939About Group A + Group B
Group A + Group B is a pre-clinical stage product being developed by Bayer for Bronchiectasis Adult. The current trial status is completed. This product is registered under clinical trial identifier NCT03383939. Target conditions include Bronchiectasis Adult.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03383939 | Pre-clinical | Completed |
Competing Products
20 competing products in Bronchiectasis Adult
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| AZD9668 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD5069 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD0292 | AstraZeneca | Phase 2 | 52 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin DPI (BAYQ3939) + Placebo | Novartis | Phase 3 | 77 |
| Placebo to Ciprofloxacin DPI (BAYQ3939) | Novartis | Pre-clinical | 23 |
| Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo | Novartis | Phase 3 | 77 |
| QBW251 + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin (Cipro, BAYQ3939) + Placebo | Novartis | Phase 2 | 52 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Aztreonam lysine | Gilead Sciences | Approved | 84 |
| AZLI | Gilead Sciences | Phase 2 | 51 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Itepekimab (SAR440340) + Placebo | Sanofi | Phase 2 | 51 |
| CSL787 + Placebo | CSL | Phase 1 | 32 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| BAY85-8501 + Placebo | Bayer | Phase 2 | 49 |